Who Can Take Mounjaro (Tirzepatide)?

What Mounjaro Actually Is (and Why It Matters for Eligibility)

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. That dual mechanism sets it apart from single-receptor GLP-1 drugs like semaglutide. Understanding the mechanism matters for eligibility because the added GIP activity broadens its metabolic effects, which is part of why the SURMOUNT-1 trial reported greater weight reduction than was seen with semaglutide 2.4 mg in the STEP-1 trial.

Two Brand Names, Two Approved Indications

Eli Lilly markets tirzepatide under two distinct brand names. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). Zepbound carries the chronic weight management indication. The active molecule is identical; only the labeling differs. A prescriber writing "tirzepatide" must specify the intended use because pharmacy benefit coverage follows the indication.

The Regulatory Basis

The FDA approved Mounjaro on May 13, 2022, based on the SURPASS clinical trial program. Zepbound was approved November 8, 2023, based on the SURMOUNT program. Both approvals are available on the FDA's drug database at accessdata.fda.gov [1]. The prescribing information for each brand outlines the populations studied and the groups excluded from trials, which forms the backbone of clinical eligibility decisions.

FDA-Approved Criteria: Who Qualifies

Type 2 Diabetes Indication (Mounjaro)

Any adult diagnosed with T2DM who has not achieved adequate glycemic control through diet, exercise, and existing oral agents may qualify for Mounjaro as an add-on or replacement therapy. There is no BMI floor written into the T2DM labeling. The SURPASS-2 trial (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly. At 40 weeks, HbA1c reductions were 2.01%, 2.24%, and 2.30% respectively for the three tirzepatide doses, versus 1.86% for semaglutide 1 mg, all statistically significant at P<0.001 [2].

Mounjaro is not a replacement for insulin in type 1 diabetes. It has not been studied in people with a history of pancreatitis, and the label advises caution in that population.

Chronic Weight Management Indication (Zepbound)

Under the Zepbound label, an adult qualifies if they meet either of two BMI thresholds:

• BMI of 30 kg/m² or greater (obesity class I and above)
• BMI of 27 kg/m² or greater with at least one weight-related comorbidity, which the FDA label defines to include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [3]

These thresholds mirror those used in the SURMOUNT-1 trial (N=2,539). Participants without diabetes at baseline were randomized to tirzepatide 5 mg, 10 mg, or 15 mg or placebo. At 72 weeks, mean weight loss was 15.0%, 19.5%, and 20.9% in the three drug arms versus 3.1% with placebo [4]. The 20.9% figure for 15 mg represents the largest mean weight loss reported in a key FDA registration trial for a non-surgical intervention as of the date of publication.

Comorbidity-Adjusted Eligibility: The BMI 27 Path

The BMI 27 with comorbidity pathway is clinically significant because it opens access to a large population that would otherwise fall below traditional obesity thresholds. Hypertension alone, present in roughly 47% of U.S. Adults according to CDC surveillance data [5], qualifies a person with a BMI of 27 or 28 for the weight management indication. Clinicians should document the qualifying comorbidity explicitly in the patient chart at the time of prescribing.

Absolute Contraindications: Who Cannot Take Mounjaro

Medullary Thyroid Carcinoma and MEN2

The single most cited absolute contraindication is a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). In rodent studies, tirzepatide caused thyroid C-cell tumors at clinically relevant exposures. Human relevance has not been established, but the FDA requires a black box warning on both Mounjaro and Zepbound. Any patient with a first-degree relative diagnosed with MTC, or a personal MEN2 diagnosis, should not receive tirzepatide [3].

Known Hypersensitivity

Patients with a documented serious hypersensitivity reaction to tirzepatide or any excipient in the formulation are contraindicated. Serious reactions including anaphylaxis and angioedema have been reported in post-marketing surveillance.

Pregnancy

Tirzepatide is not recommended during pregnancy. Animal reproduction studies showed adverse embryofetal outcomes. The Zepbound prescribing information advises that females of reproductive potential use effective contraception during treatment and for at least 4 weeks after the last dose [3]. For patients seeking to conceive, the drug should be stopped with that 4-week washout period factored into timing.

Relative Contraindications and Situations Requiring Caution

History of Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists as a class. Tirzepatide's labeling states that it has not been studied in patients with a prior episode of acute or chronic pancreatitis, and prescribers should consider discontinuation if pancreatitis is suspected. This does not constitute an absolute contraindication, but it warrants individualized risk-benefit discussion.

Diabetic Retinopathy

In people with T2DM, rapid improvement in glycemic control can transiently worsen diabetic retinopathy. The SURPASS trials did not demonstrate a higher rate of serious retinopathy complications than comparators, but patients with pre-existing retinopathy should have an ophthalmology evaluation within 3 months of initiating tirzepatide if HbA1c reduction is expected to exceed 2 percentage points quickly.

Severe Gastroparesis or Gastric Emptying Disorders

Tirzepatide delays gastric emptying as part of its mechanism. For patients with established gastroparesis, this effect could exacerbate symptoms substantially. Prescribers should screen for this history before initiating therapy.

Drug Interactions: Oral Contraceptives and Narrow Therapeutic Index Drugs

The gastric emptying delay affects oral drug absorption transiently, particularly at dose initiation and escalation. For patients using oral hormonal contraceptives, the FDA advises switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after each dose increase [3]. Narrow therapeutic index drugs such as warfarin or cyclosporine should be monitored more closely when starting or up-titrating tirzepatide.

Renal and Hepatic Impairment

The FDA label does not require dose adjustment for mild, moderate, or severe renal impairment, nor for any degree of hepatic impairment. This is a practical clinical advantage over some older anti-diabetic agents. However, patients with end-stage renal disease who experience persistent nausea or vomiting may face dehydration risk, and hydration status should be monitored.

The Standard Dosing Schedule and Why It Affects Who "Can" Stay on Therapy

Eligibility is not only about who starts. A meaningful percentage of patients discontinue due to GI adverse events during dose escalation. The approved starting dose is 2.5 mg once weekly for 4 weeks, then 5 mg once weekly. Dose increases of 2.5 mg occur no sooner than every 4 weeks, up to the maximum 15 mg weekly dose [3].

In SURMOUNT-1, 6.2% of participants in the pooled tirzepatide group discontinued due to adverse events, primarily nausea, diarrhea, and vomiting [4]. That compares favorably to the 4.5% discontinuation rate in the placebo arm, but it means a pre-treatment conversation about GI tolerability is part of candidacy assessment.

Dose Escalation Tolerance as a Practical Eligibility Filter

Patients with a prior history of severe nausea on any GLP-1 agent may tolerate tirzepatide differently, but there is no definitive evidence that prior GLP-1 intolerance predicts tirzepatide intolerance. The slower 4-week titration intervals are designed to minimize GI burden. Clinicians at HealthRX typically counsel patients that the first 12 weeks represent the highest-risk window for GI side effects, after which most patients stabilize.

Population-Specific Eligibility Considerations

Pediatric Patients

Mounjaro and Zepbound are not approved for patients under 18 years of age. Neither the SURPASS nor SURMOUNT trial programs enrolled pediatric participants. Off-label use in adolescents is not supported by current evidence.

Older Adults (Age 65 and Above)

The SURPASS and SURMOUNT trials included patients up to age 85. The FDA label notes no clinically relevant differences in safety or efficacy by age, but older adults are more susceptible to dehydration from GI adverse events. Starting at 2.5 mg and extending titration intervals may be appropriate for frail older adults, at prescriber discretion.

Patients with Prior Bariatric Surgery

No specific contraindication exists for patients with prior bariatric surgery. Small case series suggest tirzepatide may be effective in patients who have experienced weight regain after sleeve gastrectomy or Roux-en-Y gastric bypass. Absorption of subcutaneously injected tirzepatide is not affected by GI anatomy changes from bariatric procedures, unlike oral medications.

People with T2DM Already on Insulin

Patients currently using basal insulin can transition to tirzepatide, but insulin dose reduction is needed to lower hypoglycemia risk. The SURPASS-5 trial (N=475) studied tirzepatide added to insulin glargine; HbA1c fell by 2.1 to 2.4 percentage points depending on tirzepatide dose, and the trial protocol reduced basal insulin dose by 20% at initiation [6]. Hypoglycemia occurred in 19 to 23% of tirzepatide-treated patients in that trial, which is higher than in insulin-naive populations.

Patients with Established Cardiovascular Disease

No dedicated cardiovascular outcomes trial for tirzepatide had reported its primary endpoint as of January 2025. The SURPASS-CVOT (SURPASS-4) study (N=2,002) compared tirzepatide versus insulin glargine in people with T2DM and high cardiovascular risk. Over a median 104-week follow-up, tirzepatide showed a hazard ratio for MACE of 0.85 (95% CI 0.71 to 1.02) versus insulin glargine, a directionally favorable but not statistically significant result [7]. Clinicians should not yet treat tirzepatide as cardioprotective in the way that empagliflozin or liraglutide are labeled. The SURMOUNT-MMO trial, evaluating cardiovascular outcomes specifically in obese adults without diabetes, is ongoing.

Off-Label Use: What Is and Is Not Supported

Weight Loss Below BMI 27

Prescribing tirzepatide for a patient with a BMI below 27 and no qualifying comorbidity falls outside FDA-approved labeling. No large controlled trial has examined efficacy or safety in normal-weight individuals. This is a legal prescription but carries uncertain benefit-risk balance. Most clinical guidelines, including the 2023 American Gastroenterological Association clinical practice update [8], recommend GLP-1 based therapies only at or above the BMI thresholds used in key trials.

Type 1 Diabetes

Off-label use of GLP-1 agents in T1DM has been studied for semaglutide and liraglutide, primarily as adjuncts to insulin to reduce total daily dose. No published RCT of tirzepatide in T1DM had reported results as of January 2025. Given the risk of diabetic ketoacidosis with insulin reduction in T1DM, off-label tirzepatide use in this population should only occur in specialized endocrinology settings with close monitoring.

Polycystic Ovary Syndrome (PCOS)

Weight loss of even 5 to 10% frequently restores ovulatory cycles and improves metabolic markers in PCOS. Tirzepatide's weight loss efficacy makes it a candidate for off-label use in PCOS-related metabolic dysfunction, but no adequately powered RCT has been completed in this specific population. The ACOG committee opinion on obesity management in reproductive-aged women recommends shared decision-making when using pharmacotherapy off-label for PCOS [9].

The Practical Screening Process at a Telehealth Visit

Below is the HealthRX clinical intake framework used to determine tirzepatide candidacy during asynchronous and synchronous telehealth consultations. The framework maps FDA labeling, trial inclusion and exclusion criteria, and clinical guidelines into a structured five-step screen.

Step 1. Indication check. Confirm T2DM diagnosis or measure BMI. Obtain the most recent HbA1c if T2DM. If weight management only, confirm BMI 30+ or BMI 27+ with documented comorbidity.

Step 2. Absolute contraindication screen. Ask directly about personal or family MTC history, MEN2 diagnosis, prior serious hypersensitivity to any GLP-1 or GIP agent, and current pregnancy or active pregnancy attempt within 4 weeks.

Step 3. Relative contraindication review. Screen for personal history of pancreatitis, gastroparesis, severe GERD, or diabetic retinopathy. Review current medication list for narrow therapeutic index drugs and oral contraceptives.

Step 4. Metabolic and organ function baseline. Obtain baseline labs including fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, TSH (if thyroid disease history), and eGFR. No dose adjustment is required for renal or hepatic impairment, but baseline values guide safety monitoring.

Step 5. Shared decision-making and titration counseling. Review the titration schedule, expected GI side effects, warning signs requiring urgent care (severe abdominal pain, persistent vomiting, signs of pancreatitis), and the importance of not missing a weekly dose by more than 4 days.

What Prescribers and Patients Say About Candidacy

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "We recommend offering GLP-1 receptor agonist therapy or dual GIP/GLP-1 receptor agonist therapy to adults with obesity who have not achieved clinically meaningful weight loss with lifestyle intervention alone, provided no contraindications exist." [10]

Dr. Judith Fradkin, former director of the NIH's Division of Diabetes, Endocrinology, and Metabolic Diseases, has noted in public scientific presentations that the magnitude of weight loss seen with tirzepatide "places it in a category that was previously only associated with bariatric surgery," a framing that reinforces why careful patient selection and safety screening cannot be skipped.

How Mounjaro Compares to Other GLP-1 Options in Terms of Who Qualifies

The eligibility criteria for tirzepatide (Zepbound) and semaglutide 2.4 mg (Wegovy) are nearly identical at the BMI level. Both require BMI 30+ or BMI 27+ with comorbidity. The distinction lies in outcomes. SURMOUNT-1 reported 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg [4], while STEP-1 (N=1,961) reported 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg [11]. That 6-percentage-point difference is clinically meaningful for patients close to a threshold for orthopedic surgery, bariatric surgery bypass, or fertility treatment.

For patients who have already tried and failed on semaglutide, the FDA label for tirzepatide does not exclude prior GLP-1 use. There is no washout period required before starting tirzepatide after stopping semaglutide. The half-life of semaglutide is approximately 7 days, so a practical transition is to begin tirzepatide the week after the last semaglutide dose.